Compare Icl Group Ltd (ICL) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Novo Nordisk A/S — how do they compare? Icl Group Ltd trades at $5.03 (market cap $6.47B), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 25.6× Icl Group Ltd's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Novo Nordisk A/S for 116 Days on average.
| ICL | NVO | |
|---|---|---|
Market Cap | $6.47B | $165.31B |
Volume | 1,387,140 | 11,432,838 |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $63.98 |
52-Week Low | $4.80 | $35.29 |
Typical Hold Time | 56 Days | 116 Days |
Enterprise Value | $9.11B | $179.56B |
Dividend Yield | 4.11% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL Group trades at $5.015, down 1.28% today, with a bearish technical outlook despite recent earnings beats. The company maintains stable cash flow generation with $1.06B from operations in 2025, though revenue has declined from $10.0B in 2022 to $7.15B in 2025. Recent Q2 2026 results showed earnings of $0.12 per share, beating estimates, and the company announced a dividend of $0.06 payable September 16, 2026.
While ICL shows fundamental stability with reasonable valuation metrics (P/E 20.83, P/S 0.84), the stock faces headwinds from declining profitability margins and bearish technical signals. Analyst consensus remains neutral with 100% hold ratings, though the $6.08 price target suggests 21% upside potential from current levels.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
